SS-31: The Cardiolipin-Targeting Mitochondrial Peptide at the Frontier of Energy Medicine and Rare Disease Treatment

Discovery and Background

SS-31, known by multiple designations including elamipretide, MTP-131, Bendavia, and most recently its FDA-approved brand name Forzinity, is a synthetic tetrapeptide with the sequence D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2. It belongs to the Szeto-Schiller (SS) peptide family, a class of aromatic-cationic tetrapeptides developed through a collaboration between Dr. Hazel Szeto at Weill Cornell Medical College and Dr. Peter Schiller at the Clinical Research Institute of Montreal. The discovery was serendipitous in the truest sense: Szeto and Schiller were developing novel opioid receptor agonist peptides when they noticed that certain peptides with alternating cationic and aromatic amino acid motifs were cell-permeable in ways that defied conventional pharmacological expectations. Subsequent investigation revealed that these peptides were not merely crossing cell membranes but concentrating specifically and dramatically at the inner mitochondrial membrane, accumulating to levels 1,000 to 5,000 times higher than surrounding tissue without any driving force from the mitochondrial membrane potential.

This discovery was foundational because it contradicted the established understanding of how compounds reach mitochondria. The prevailing approach to mitochondrial drug delivery at the time involved conjugating compounds to triphenylphosphonium cations, which exploit the large negative membrane potential of healthy mitochondria to drive accumulation. This approach worked in healthy mitochondria but failed in diseased or depolarized ones, precisely the situations where mitochondrial therapy is most needed. SS peptides, including SS-31, were found to accumulate at the inner mitochondrial membrane through an energy-independent mechanism driven by their interaction with cardiolipin, a unique phospholipid found almost exclusively on the inner mitochondrial membrane. This cardiolipin-targeted accumulation mechanism means SS-31 reaches diseased and depolarized mitochondria as effectively as healthy ones, a property of fundamental therapeutic importance.

The SS designation reflects the peptide series developers, Szeto and Schiller. The "31" designation identifies the specific sequence within the series found to have optimal mitochondrial targeting and therapeutic properties. In pharmaceutical development, the compound was advanced by Stealth BioTherapeutics, a clinical-stage company that licensed the peptide technology from the Cornell Research Foundation. In September 2025, following an FDA advisory committee meeting in October 2024 that concluded elamipretide was effective for the treatment of Barth syndrome, the FDA granted accelerated approval to Forzinity as the first approved treatment for Barth syndrome, a rare and life-threatening mitochondrial disorder affecting primarily males through mutations in the TAFAZZIN gene that disrupt cardiolipin remodeling. This approval marked the culmination of decades of scientific work and the validation of the entire cardiolipin-targeting therapeutic approach.

To understand SS-31's significance, it is necessary to understand what cardiolipin does and what happens when it is damaged. Cardiolipin is an unusual dimeric phospholipid with two phosphate headgroups and four acyl chains, comprising roughly 10 to 20% of the total lipids within the inner mitochondrial membrane. It is the structural organizer of the respiratory chain, mediating interactions between electron transport chain complexes and enabling their assembly into supercomplexes that perform oxidative phosphorylation with maximum efficiency and minimum electron leakage. Cardiolipin also plays central roles in mitochondrial dynamics including fission and fusion, in the regulation of the mitochondrial permeability transition pore, in the intrinsic apoptotic pathway, and in mitophagy, the selective autophagy of damaged mitochondria. With aging, disease, and ischemic injury, cardiolipin becomes peroxidized by reactive oxygen species generated at the electron transport chain, losing its structural integrity and impairing all of the functions it coordinates. The resulting cascade of mitochondrial dysfunction, reduced ATP synthesis, increased ROS generation, and dysregulated apoptotic signaling drives the pathology of an extraordinarily wide range of conditions, from heart failure and kidney disease to neurodegeneration and sarcopenia.

Research Overview

SS-31's research base spans over 150 peer-reviewed publications, 18 completed or ongoing human clinical trials, and two decades of investigation across cell culture, animal models, and human populations. The breadth of conditions in which it has shown preclinical benefit is exceptional: heart failure, primary mitochondrial myopathy, Barth syndrome, atherosclerotic renal artery stenosis, acute kidney injury, diabetic nephropathy, glomerulosclerosis, ischemia-reperfusion injury across multiple organs, cognitive impairment from anesthesia and aging, Alzheimer's disease, Parkinson's disease, diabetic retinopathy, age-related macular degeneration, osteoarthritis, pulmonary fibrosis, noise-induced hearing loss, sarcopenia, and Friedreich's ataxia.

The flagship human clinical program is the TAZPOWER trial in Barth syndrome. The phase 2/3 randomized, double-blind, placebo-controlled crossover trial enrolled 12 individuals with genetically confirmed Barth syndrome and administered elamipretide at 40 mg daily subcutaneously for 12 weeks in each treatment arm. Part 1 of the trial did not meet its primary endpoints of six-minute walk test improvement and BTHS symptom assessment scale, a result that initially dampened enthusiasm. However, the 168-week open-label extension that followed told a more compelling story. Eight patients reaching the 168-week visit demonstrated sustained long-term tolerability and efficacy, with significant improvements in functional assessments including six-minute walk test performance and BTHS symptom assessment scores, alongside cardiac improvements including increased cardiac stroke volumes that were not apparent in the shorter 12-week controlled period. This timeline dependency is mechanistically meaningful: cardiolipin remodeling and mitochondrial structural restoration are not acute pharmacological events but require sustained treatment to manifest as functional improvements.

In the cardiovascular domain, a phase 2a clinical trial in patients with atherosclerotic renal artery stenosis treated with elamipretide plus stent revascularization versus stent revascularization alone demonstrated that elamipretide prevented the fractional hypoxia increase that normally follows revascularization in the placebo group, and produced significant improvements in stenotic kidney renal blood flow at three months follow-up in the treated group only, providing direct human evidence of ischemia-reperfusion protection in a clinically meaningful cardiovascular context.

The ReCLAIM study, a randomized, double-blind, placebo-controlled, multicenter phase 2 trial in patients over 55 with dry age-related macular degeneration, evaluated elamipretide's ability to slow geographic atrophy progression and preserve retinal function. While the primary endpoints of geographic atrophy progression reduction did not reach statistical significance, secondary endpoints showed improvements in low-luminance vision and preservation of the ellipsoid zone integrity, the photoreceptor layer most directly responsible for visual acuity. The failed heart failure and primary mitochondrial myopathy phase 3 trials represent the most significant setbacks in the clinical program, with both trials failing to meet primary endpoints in randomized, controlled settings. These results warrant careful interpretation: the primary mitochondrial myopathy crossover trial showed improvements in fatigue scores that did not reach statistical significance in the 12-week controlled period but became significant in the longer-term open-label extension, consistent with the Barth syndrome experience and suggesting that trial duration may have been an important limiting factor.

A 2025 systematic review published in the International Journal of Molecular Sciences identified ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, as a common mechanistic pathway underlying many of the conditions where SS-31 demonstrates therapeutic benefit, with cardiolipin peroxidation representing a direct link between mitochondrial dysfunction and ferroptotic cell death that SS-31's mechanism specifically interrupts.

Key Mechanisms

Cardiolipin Binding and Inner Mitochondrial Membrane Stabilization

SS-31's defining and foundational mechanism is its selective binding to cardiolipin on the inner mitochondrial membrane. The peptide's alternating cationic and aromatic amino acid architecture allows it to partition into the interfacial region of cardiolipin-rich membranes through a combination of electrostatic attraction between its positively charged residues and the negatively charged cardiolipin headgroups, and hydrophobic insertion of its aromatic dimethyltyrosine residue into the membrane bilayer. This dual interaction mode produces high-affinity, selective binding to cardiolipin that accumulates the peptide to concentrations 1,000 to 5,000 times higher than surrounding cytoplasm. Cross-linking mass spectrometry experiments identified 12 mitochondrial proteins as direct interaction partners of SS-31, all of them known cardiolipin binders involved in either ATP production through oxidative phosphorylation or in 2-oxoglutarate metabolic processes, confirming that SS-31's therapeutic effects are mediated through interactions with the protein machinery that cardiolipin organizes.

Cytochrome c Peroxidase Inhibition and Electron Transport Restoration

When cardiolipin becomes peroxidized, cytochrome c, normally a mobile electron carrier shuttling electrons between Complex III and Complex IV of the electron transport chain, converts to a peroxidase enzyme that further oxidizes cardiolipin in a destructive positive feedback loop. SS-31 interrupts this cycle by modulating the hydrophobic interaction between cytochrome c and cardiolipin, restoring cytochrome c's electron carrier function while inhibiting its peroxidase activity. The result is reduced electron leakage at the electron transport chain, reduced ROS generation, restored electron flow toward Complex IV and ATP synthase, and arrest of the cardiolipin peroxidation cascade. This mechanism makes SS-31 fundamentally different from conventional antioxidants that circulate throughout the body neutralizing ROS after they are generated. SS-31 prevents ROS from being produced in the first place by stabilizing the electron transport infrastructure at its source.

Respiratory Supercomplex Assembly and ATP Synthase Support

SS-31-interacting proteins identified by cross-linking mass spectrometry fall predominantly into the oxidative phosphorylation pathway, including components of Complex I, Complex III, cytochrome c oxidase, and ATP synthase. By stabilizing cardiolipin's interactions with these complexes and supporting their assembly into supercomplexes, SS-31 improves the efficiency of electron transfer between respiratory chain components, reduces energy dissipation as heat and ROS, and increases the yield of ATP per molecule of oxygen consumed. In failing human hearts, elamipretide has been shown to improve mitochondrial function directly, with ex vivo studies of mitochondria from heart failure patients demonstrating restored respiratory function following SS-31 treatment.

Mitochondrial Permeability Transition Pore Inhibition

SS-31 inhibits the opening of the mitochondrial permeability transition pore (mPTP), a catastrophic event in which the inner mitochondrial membrane becomes non-selectively permeable, collapsing the proton gradient, releasing cytochrome c and other pro-apoptotic factors into the cytoplasm, and triggering mitochondrial swelling and cell death. mPTP opening is a central mediator of cell death following ischemia-reperfusion injury in the heart, kidney, and brain, and its inhibition is a validated therapeutic target in these contexts. SS-31's inhibition of mPTP opening occurs through its cardiolipin-stabilizing mechanism, as cardiolipin integrity is required for appropriate mPTP regulation, providing a direct link between SS-31's membrane-level interactions and its organ-protective effects in ischemic contexts.

Ferroptosis Protection via Cardiolipin Peroxidation Prevention

Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a unifying mechanism in multiple conditions where SS-31 demonstrates benefit. Cardiolipin, with its four polyunsaturated acyl chains, is among the most ferroptosis-vulnerable lipids in the cell. By preventing cardiolipin peroxidation through cytochrome c peroxidase inhibition and direct antioxidant activity of its dimethyltyrosine residue, which interacts with oxygen radicals to form unreactive tyrosine radicals that couple together as di-tyrosine, SS-31 protects against ferroptotic cell death across multiple tissue types. In 2024 research, SS-31 was shown to prevent seizures in epilepsy models through inhibition of ferroptosis in hippocampal neurons via p38 MAPK phosphorylation suppression, identifying a neurological mechanism with broad relevance to conditions characterized by oxidative neuronal stress.

Mitochondrial Dynamics and Structural Restoration

SS-31 normalizes mitochondrial fission-fusion dynamics in diseased states where mitochondria become fragmented and dysfunctional. In failing heart models, elamipretide normalized abnormalities in mitochondrial dynamics, reducing excessive fission and restoring the tubular morphology associated with efficient mitochondrial function. In Barth syndrome cardiac mitochondria, SS-31 treatment ameliorated the abnormal mitochondrial ultrastructure, accumulated vacuoles, and pro-fission conditions, improving mitochondrial respiratory chain efficiency at 48 weeks without changes in the underlying cardiolipin composition, demonstrating that structural and functional restoration can be achieved even when the underlying genetic defect causing cardiolipin abnormalities remains present.

Common Applications

Barth Syndrome and Primary Mitochondrial Diseases

Barth syndrome, caused by TAFAZZIN gene mutations that disrupt cardiolipin remodeling, represents the first approved indication for elamipretide and the clearest proof of concept for the cardiolipin-targeting therapeutic approach. The compound's accelerated FDA approval as Forzinity in September 2025, following 168-week open-label extension data demonstrating sustained improvements in exercise capacity, symptom burden, and cardiac function, established elamipretide as the first disease-modifying therapy for any primary mitochondrial disorder. The expanded access program initiated in December 2020 by Stealth BioTherapeutics provides a pathway for individuals with genetically confirmed rare mitochondrial diseases or serious clinical manifestations of mitochondrial dysfunction to access elamipretide under physician supervision while broader clinical development continues.

Cardiovascular Disease and Ischemia-Reperfusion Protection

The heart, as the most metabolically active organ in the body with the highest density of mitochondria per gram of tissue, represents both the primary target and the most extensively studied application domain for SS-31. Preclinical heart failure models across multiple species and multiple etiologies show consistent improvements in mitochondrial function, cardiac output, and exercise tolerance. The human renal artery stenosis trial demonstrating protection against revascularization-induced ischemia-reperfusion injury provided the most direct clinical evidence of SS-31's cardiovascular protective mechanism. Ongoing cardiovascular phase 2 investigations in heart failure with reduced ejection fraction continue the clinical development program. In longevity protocols, SS-31 is frequently paired with Cardiogen, the cardiac bioregulator addressing fibrosis and cardiomyocyte gene expression, to create a cardiovascular mitochondrial protection stack that addresses both the bioenergetic and structural dimensions of cardiac aging.

Kidney Disease and Acute Kidney Injury Protection

SS-31 is rapidly absorbed after subcutaneous administration and concentrates preferentially in the kidney, making renal protection one of its most pharmacokinetically favored applications. Preclinical data across multiple kidney disease models, including ischemia-reperfusion injury, diabetic nephropathy, hypertensive nephrosclerosis, and obesity-associated nephropathy, consistently demonstrate reduced oxidative stress, preserved podocyte integrity, reduced proteinuria, and slowed progression of structural kidney damage. The renal artery stenosis clinical trial provided direct human evidence of kidney protection in an ischemic context. For individuals with chronic kidney disease, diabetic nephropathy, or those at risk of contrast nephropathy from radiological procedures, SS-31's renal concentration and mitochondrial protective properties create a compelling mechanistic rationale for its use.

Age-Related Muscle Loss and Sarcopenia

Mitochondrial dysfunction is a primary driver of the age-related skeletal muscle loss called sarcopenia, with declining mitochondrial bioenergetic capacity reducing the energy available for protein synthesis and muscle maintenance while increasing the oxidative stress that accelerates protein degradation. In aged rodent models, SS-31 reversed age-related functional deficits in skeletal muscle, improving muscle fiber integrity, reducing oxidative damage markers, and restoring contractile force production. Remarkably, a 2025 aging study demonstrated that SS-31 can reverse age-related muscle and heart dysfunction in animal models without changes in epigenetic or transcriptomic markers of aging, suggesting that functional restoration through direct mitochondrial repair can occur independently of the broader epigenetic aging clock, an important mechanistic distinction from epigenetically-acting interventions like bioregulators. SS-31 is most commonly used in sarcopenia and muscle aging contexts as part of a mitochondrial peptide stack alongside MOTS-c and Humanin.

Neurodegenerative Disease and Cognitive Protection

While SS-31 crosses the blood-brain barrier at concentrations lower than its renal or cardiac concentrations, the brain's extraordinary dependence on mitochondrial ATP production and extreme vulnerability to oxidative stress make even partial mitochondrial protection potentially meaningful in neurological contexts. Preclinical studies have demonstrated that SS-31 improves cognitive function in aged mice exposed to anesthesia-induced mitochondrial dysfunction, reduces amyloid-related mitochondrial toxicity in Alzheimer's disease models, protects dopaminergic neurons in Parkinson's disease models, and prevents seizures in epilepsy models through ferroptosis inhibition. The compound reduces neuroinflammation and improves synaptic mitochondrial function in models of cognitive impairment. For individuals at elevated risk of neurodegenerative disease or experiencing age-related cognitive decline where mitochondrial dysfunction is a contributing factor, SS-31 represents a mechanistically grounded intervention that complements the BDNF-targeting approaches of compounds like Semax and Selank.

Ocular Disease and Age-Related Macular Degeneration

Photoreceptors in the retina have the highest mitochondrial density of any cell type in the body, making them exquisitely vulnerable to the mitochondrial dysfunction that characterizes aging. The ReCLAIM phase 2 trial in age-related macular degeneration, while not meeting primary endpoints for geographic atrophy progression reduction, demonstrated improvements in low-luminance vision and ellipsoid zone preservation, providing a signal of photoreceptor protection that warrants continued investigation. Preclinical studies showing prevention and correction of vision loss in diabetic mice, improved survival of human retinal endothelial and pigment epithelial cells, and protection of trabecular meshwork cells relevant to glaucoma support a broad ocular protective profile mechanistically grounded in the retina's mitochondrial dependence.

References

1. https://www.sciencedirect.com/science/article/pii/S0753332225002501
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7247319/
3. https://www.pnas.org/doi/10.1073/pnas.2002250117
4. https://www.jbc.org/article/S0021-9258(17)50276-8/fulltext
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/

Note: This list compiles unique sources referenced throughout the article. For a full bibliography, including additional studies mentioned in the content, consult the original research compilations or databases like PubMed.